 |
|
Cost-Effectiveness of Denosumab for the Treatment of Postmenopausal Osteoporosis in South Korea
Jung-Yoon Kang, Leejung Choi, Ben Johnson, Hyowon Yang
J Bone Metab. 2022;29(2):83-92. Published online 2022 May 31 DOI: https://doi.org/10.11005/jbm.2022.29.2.83
|
|
Citations to this article as recorded by
 Long-Term Efficacy and Safety of Denosumab: Insights beyond 10 Years of Use
Jeonghoon Ha, Youn-Ju Lee, Jinyoung Kim, Chaiho Jeong, Yejee Lim, Jeongmin Lee, Ki-Hyun Baek
Endocrinology and Metabolism.2025; 40(1): 47. CrossRef Cost-consequence analysis of continuous denosumab therapy for osteoporosis treatment in South Korea
Seungju Cha, Minjeong Sohn, Hyowon Yang, Eric J. Yeh, Ki-Hyun Baek, Jeonghoon Ha, Hyemin Ku
BMC Musculoskeletal Disorders.2024;[Epub] CrossRef Comparative effectiveness and safety outcomes between denosumab and bisphosphonate in South Korea
ChulHyoung Park, Chungsoo Kim, Rae Woong Park, Ja Young Jeon
Journal of Bone and Mineral Research.2024; 39(7): 835. CrossRef
|